天康生物(002100.SZ):將天康生物製藥100%股權無償劃轉給天康製藥(蘇州)
格隆匯 12 月 23日丨天康生物(002100.SZ)公佈,公司於2020年12月23日召開了第七屆董事會第十二次會議,審議並通過了《關於全資子公司股權內部劃轉的議案》,同意將公司直接持股的全資子公司天康生物製藥有限公司100%股權無償劃轉給公司全資子公司天康製藥(蘇州)有限公司。同時,授權公司管理層辦理股權劃轉的相關事宜。
劃轉完成後,天康生物製藥有限公司將成為天康製藥(蘇州)有限公司的全資子公司,同時為公司的孫公司。此次股權劃轉是公司合併報表範圍內企業之間股權的劃轉,不涉及合併報表範圍變化。
根據相關法律法規及《公司章程》的規定,上述事項在董事會決策權限內,無需提交股東大會審議。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.